Trial Section
Home / Trial Section / Clinical Trial| Indication | Department | Study Title | Study Phase | Investigator | Contact Person | Status |
|---|---|---|---|---|---|---|
| 無 | Chest Medicine | Taiwan Real-world low-dose computed tomography screening behavIor and Outcome research for high risk subjects based on Health Promotion Administration-part A: Questionnaire survey -part B: LDCT screening outcome and management | -- | Inn-Wen Chong | 洪鳳君 | On-going |
| Chronic Obstructive Pulmonary Disease | Chest Medicine | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Phase III | Chau-Chyun Sheu | 吳珮驊 | On-going |
| Hepatitis | Hepatobiliary and Pancreatic Medicine | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Phase II | Chia-Yen Dai | 蔡宜錚 | On-going |
| Non-Small Cell Lung Cancer | Chest Medicine | A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (FURVENT) | Phase III | Jen-Yu Hung | 林容君 | On-going |
| Kidney Disease | Nephrology | A Study to Identify and Characterise Patients with Chronic Kidney Disease and Proteinuria | -- | Yi-Wen Chiu | 陳宜霈 | On-going |
| Diabetic Foot Ulcer | Plastic Surgery | A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcer | Phase III | SHU-HUNG HUANG | 鄭琪云 | On-going |
| Breast Cancer | Breast Oncology and Surgery | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2?) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH?]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy | Phase III | Ming-Feng Hou | 李安婷 | On-going |
| Carbapenem-resistant Enterobacterales 感染症 | Chest Medicine | A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection due to Carbapenem-Resistant Enterobacterales | Phase III | Chau-Chyun Sheu | 陳怡臻 | On-going |
| Hypertension | Cardiology | A multi-center, randomized, double-blind, parallel-group, 20-week dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with resistant hypertension | Phase II | Tsung-Hsien Lin | 江書瑜 | On-going |
| Gastric Cancer | Colorectal Surgery | A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (Aspen-06) | Phase II | WANG,JAW-YUAN | On-going |
← Please slide to the left for more information